Scott M. Lippman, M.D.: Short CV

More documents

Recommendations

Info

$Week 05\G, A and R 02.pdf$

Curriculum Vitae Scott M. Lippman, M.D. Page 32 67. Sabichi AL, Lippman SM. COX-2 inhibitors and other NSAIDs in bladder and prostate cancer. Prog Exp Tumor Res 37:163-78, 2003. 68. Klein EA, Lippman SM, Thompson IM, Goodman PJ, Albanes D, Taylor PR, Coltman C. The selenium and vitamin E cancer prevention trial. World J Urol 21:21-7, 2003. 69. Sabichi AL, Lippman SM. COX-2 inhibitors and other nonsteroidal antiinflammatory drugs in genitourinary cancer. Semin Oncol 31:36-44, 2004. 70. Thompson IM, Goodman PA, Tangen CM, Leach RJ, Canby-Hagino E, Klein EA, Lippman SM. Chemoprevention of prostate cancer. Grand Rounds in Urology (In press). c. Editorials 1. Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 17:691-4, 1989. 2. Lippman SM, Spitz MR (eds.). Intervention in the premalignant process. Cancer Bull 43:473-4, 1991. 3. Lippman SM, Hong WK. Not yet standard: retinoids versus second primary tumors. J Clin Oncol 11:1204-7, 1993. 4. Lippman SM, Hong WK. The future of controlling lung carcinogenesis: molecular biomarkers. Oncology 7:31-2, 1993. 5. Benner SE, Lippman SM, Hong WK. Chemoprevention of second primary tumours: a model for intervention trials. Eur J Cancer 6:727-9, 1994. 6. Lippman SM, Hong WK. 13-cis-retinoic acid plus interferon-α in solid tumors: keeping the cart behind the horse. Ann Oncol 5:391-3, 1994. 7. Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. N Engl J Med 344:1323-6, 2001. 8. Taylor PR, Parnes HL, Lippman SM. Science peels the onion of selenium effects on prostate carcinogenesis. J Natl Cancer Inst 96:645-7, 2004. 9. Duffield-Lillico AJ, Shureiqi I, Lippman SM. Can selenium prevent colorectal cancer? A signpost from epidemiology. J Natl Cancer Inst 96:1645-47, 2004. 10. Lippman SM, Levin B. Cancer prevention: strong science and real medicine. J Clin Oncol 23:249-53, 2005. 11. Lippman SM, Dannenberg AJ. A prime-time interaction, EGFR and COX2. Clin Cancer Res (In press). d. Other Articles 1. Lippman SM, Fleischer EA. Study of the synthetic, kinetic and spectral properties of three porhyrin isomers: the meso-tetra (N-Methyl 2-, 3-, and 4- Pyridyl) porphine. J Undergrad Res Biol Sci (UCI) 5:68-77, 1976. 2. Geller J, Albert J, Nachtscheim D, Loza D, Lippman S. Steroid levels in cancer of the prostate--markers of tumor differentiation and adequacy of anti-androgen therapy. Prog Clin Biol Res 33:103-11, 1979.
Curriculum Vitae Scott M. Lippman, M.D. Page 33 3. Cunningham JR, Lippman SM, Renie WA, Francomano CA, Maumenee IH, Pyeritz RE. Pseudoxanthoma elasticum: treatment of gastrointestinal hemorrhage by arterial embolization and observations on autosomal dominant inheritance. Johns Hopkins Med J 147:168-73, 1980. 4. Lippman SM, Buzaid AC, Lizak GE, Grumet FC. Post-transfusion purpura: a review. Hematol Rev 2:45-62, 1987. 5. Lippman SM, Lee JS, Lotan R, Hong WK. Chemoprevention of upper aerodigestive tract cancers: a report of the third Upper Aerodigestive Cancer Task Force workshop. Head Neck 12:5-20, 1990. 6. Benner SE, Lippman SM, Hong WK. The role of retinoids in preventing second lung cancers. Lung Cancer 9:343-50, 1993. 7. Lee JS, Lippman SM, Hong WK, Ro J, Lotan R, Hittelman WN. Biomarkers in chemoprevention trials. Lung Cancer 9:361-8, 1993. 8. McCaskill-Stevens W, Hawk ET, Flynn PJ, Lippman SM. National Cancer Institute-supported cancer chemoprevention research: coming of age. J Clin Oncol (supplement)17:53-62, 1999. 9. Hong WK, Spitz MR, Lippman SM. Cancer chemoprevention in the 21 st century: genetics, risk modeling, and molecular targets. J Clin Oncol 18:9s-18s, 2000. 10. Lippman SM, Spitz MR. Lung cancer chemoprevention: an integrated approach. J Clin Oncol 19:74S-82S, 2001. 11. Lee JJ, Lieberman R, Sloan JA, Piantadosi S, Lippman SM. Design considerations for efficient prostate cancer chemoprevention trials. Urology 57:205-12, 2001. 12. Lieberman R, Nelson WG, Sakr WA, Meyskens FL, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM. Executive summary of the National Cancer Institute workshop: highlights and recommendations. Urology 57:4-27, 2001. 13. Sabichi AL, Lippman SM. COX-2 inhibitors and other NSAIDs in bladder and prostate cancer. Prog Exp Tumor Res 37:163-78, 2003. 14. Klein EA, Lippman SM, Thompson IM, Goodman PJ, Albanes D, Taylor PR, Coltman C. The selenium and vitamin E cancer prevention trial. World J Urol 21:21-7, 2003. 15. Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, Coltman C. SELECT: the selenium and vitamin E cancer prevention trial. Urol Oncol 21:59-65, 2003. e. Abstracts (past 5 years) 1. Strom SS, Clayman GL, El-Naggar AK, Goepfert H, Lippman SM, Duvic M, Kripke ML. Aggressive squamous cell carcinoma of the head and neck: clinical and epidemiologic risk factors. Proc Seventh World Congress on Cancers of the Skin, p 124, 1998. 2. Wei Q, Strom SS, Cheng L, Wang L, Guo Z, Lippman SM, Clayman GL, El- Naggar A, Duvic M, Kripke ML. DNA repair for UV damage and non-melanoma skin cancer. Proc Seventh World Congress on Cancers of the Skin, p 109, 1998.
Page 1 and 2: NAME: Scott M. Lippman, M.D. CURRIC
Page 3 and 4: Curriculum Vitae Scott M. Lippman,
Page 31: Curriculum Vitae Scott M. Lippman,

Scott M. Lippman, M.D.: Short CV

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?